Topical Sirolimus clinical trials
How each study uses Topical Sirolimus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Topical Sirolimus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2015 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2015 | 2 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Nobelpharma (4) · Columbia University (1) · Nemours Children's Clinic (1) · University Hospital, Tours (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Topical Sirolimus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Topical TOR-582 Treatment of Epistaxis in HHTNot yet recruitingPhase 1Columbia UniversityNCT07667413Written as Topical sirolimus ointment
- Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible LesionsTerminatedPhase 1Nemours Children's ClinicNCT04172922Written as Topical Sirolimus
- A Long-term Study of NPC-12G Gel in Neurofibromatosis Type ITerminatedPhase 3NobelpharmaNCT04461886Written as NPC-12G gel
- NPC-12G Gel 0.2% Sirolimus PK Bridging StudyCompletedPhase 1NobelpharmaNCT03972462Written as NPC-12G Gel 0.2%
- Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexCompletedPhase 3NobelpharmaNCT02634931Written as NPC-12G gel
- Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)CompletedPhase 3NobelpharmaNCT02635789Written as NPC-12G gel
- Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral LichenTerminatedPhase 3University Hospital, ToursNCT01061853Written as TOPICAL SIROLIMUS (RAPAMUNE*)